AstraZeneca’s experimental oral therapy saracatinib — originally developed to treat certain cancers — was found to be at least…
Articles by Marta Figueiredo, PhD
The levels of transforming growth factor-beta-induced protein (TGFBI), a molecule involved in lung development and cancer, are significantly increased in cellular…
Cymerus mesenchymal stem cells (MSCs), Cynata Therapeutics’ experimental cell therapy, significantly lowered the levels of pro-inflammatory and pro-scarring molecules…
Mesenchymal stem cells (MSCs) grown in three-dimension (3D) conditions produce tiny extracellular vesicles (EVs) that do not retain the anti-scarring…
The experimental oral therapy AMP945, from Amplia Therapeutics, is as effective as the approved therapy Ofev (nintedanib) at…
Inconsistent results in the final planned preclinical study of NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF),…
Blade Therapeutics’ experimental oral therapy, Cudetaxestat (BLD-0409), was found to significantly reduce lung scarring (fibrosis) and the levels of…
Boehringer Ingelheim’s experimental oral therapy, BI 1015550, slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), regardless…
Using nanoparticles to deliver an anti-scarring RNA molecule to pro-scarring lung macrophages — a type of immune cell — prevented…
Eperisone — an oral muscle relaxant used to treat muscle spasms and rigidity — significantly eased lung scarring and improved lung…